{"id":23881,"date":"2022-01-12T20:25:35","date_gmt":"2022-01-12T17:25:35","guid":{"rendered":"https:\/\/zdmaa.com\/immunotherapy-for-breast-cancer-remains-elusive\/"},"modified":"2022-01-12T23:04:23","modified_gmt":"2022-01-12T20:04:23","slug":"immunotherapy-for-breast-cancer-remains-elusive","status":"publish","type":"post","link":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/","title":{"rendered":"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor"},"content":{"rendered":"

Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor<\/span><\/span><\/span><\/span><\/p>\n

\n

T<\/span><\/span><\/span> , farkl\u0131 kanser t\u00fcrlerine sahip baz\u0131 hastalar i\u00e7in d\u00fczinelerce yeni tedavi se\u00e7ene\u011fiyle imm\u00fcnoterapi \u00e7a\u011f\u0131n\u0131 vaaz etti. <\/span>ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA), ilk kontrol noktas\u0131 inhibit\u00f6r\u00fcn\u00fc onaylad\u0131: ipilimumab (Yervoy <\/span><\/span>\u00ae<\/span><\/span><\/sup> ) \u2014 2011’de metastatik melanomlu hastalar\u0131 tedavi etmek i\u00e7in. <\/span>\u015eu anda, onaylanm\u0131\u015f kontrol noktas\u0131 inhibit\u00f6rlerinin alt\u0131s\u0131, en yayg\u0131n kanser t\u00fcrlerinden baz\u0131lar\u0131n\u0131 tedavi etmek i\u00e7in kullan\u0131lmaktad\u0131r. <\/span>Ancak baz\u0131 akci\u011fer, b\u00f6brek, mesane ve di\u011fer kanser t\u00fcrlerine sahip hastalar bu yeni ila\u00e7lar\u0131 al\u0131rken, Amerika Birle\u015fik Devletleri’nde en s\u0131k te\u015fhis edilen cilt d\u0131\u015f\u0131 kanser olan meme kanseri hastalar\u0131n\u0131n \u00e7o\u011fu hala beklemektedir.<\/span><\/span><\/p>\n

“Bize imm\u00fcnoterapi ve meme kanseri hakk\u0131nda soru soran hastalardan \u00e7ok fazla soru al\u0131yoruz. Bir\u00e7ok klinik \u00e7al\u0131\u015fma var, ancak \u015fu ana kadar bu tedavi G\u0131da ve \u0130la\u00e7 \u0130daresi taraf\u0131ndan onaylanmad\u0131.” <\/span><\/span>\u2014Sramila Ethal, MD, hematolog, Philadelphia’daki hastanemizde onkolog ve onkolog<\/span><\/span><\/em><\/p><\/blockquote>\n

Kontrol noktas\u0131 inhibit\u00f6rleri nas\u0131l \u00e7al\u0131\u015f\u0131r?<\/span><\/span><\/h2>\n

Kontrol noktas\u0131 inhibit\u00f6rleri, kanser h\u00fccrelerinin ba\u011f\u0131\u015f\u0131kl\u0131k sisteminden gizlemek i\u00e7in kulland\u0131\u011f\u0131 sinyalleri bloke ederek \u00e7al\u0131\u015f\u0131r. <\/span>Bu ila\u00e7lar\u0131n \u00e7o\u011fu, ba\u011f\u0131\u015f\u0131kl\u0131k veya kanser h\u00fccrelerinde PD-1 veya PD-L1 sinyal resept\u00f6rlerini hedefler. <\/span>Ara\u015ft\u0131rmalar, t\u00fcm vakalar\u0131n y\u00fczde 20’sini olu\u015fturan \u00fc\u00e7l\u00fc negatif meme kanserli hastalar\u0131n, di\u011fer meme kanseri t\u00fcrlerine sahip hastalara g\u00f6re kontrol noktas\u0131 inhibit\u00f6rlerine daha iyi yan\u0131t verdi\u011fini g\u00f6steriyor. <\/span>Di\u011fer \u00e7al\u0131\u015fmalar, baz\u0131 meme kanserlerinin y\u00fcksek d\u00fczeyde PD-L1 i\u00e7erebilece\u011fini d\u00fc\u015f\u00fcnd\u00fcrmektedir.<\/span><\/span><\/p>\n

Ancak bilim adamlar\u0131, baz\u0131 kanserlerin bu ila\u00e7lara neden tepki verdi\u011fini ve di\u011ferlerinin neden vermedi\u011fini tam olarak anlam\u0131yorlar. <\/span>“Soru \u015fu: \u00dc\u00e7l\u00fc negatif bir kanseri yan\u0131t verme olas\u0131l\u0131\u011f\u0131n\u0131 art\u0131ran nedir?” <\/span>Philadelphia hastanemizde onkolog olan Shaima Kazemi diyor. <\/span>“T\u00fcm akci\u011fer kanserleri imm\u00fcnoterapiye yan\u0131t vermez. T\u00fcm melanomlar yan\u0131t vermez. Yan\u0131t verme e\u011filiminde olan bir kanser alt b\u00f6l\u00fcm\u00fc vard\u0131r. Bu duyarl\u0131l\u0131\u011f\u0131 de\u011ferlendirmenin birka\u00e7 yolu vard\u0131r. PD-L1 bunlardan sadece biridir ve ideal de\u011fildir.”<\/span><\/span><\/p>\n

\u00dc\u00e7l\u00fc negatif meme kanserleri ayr\u0131ca, kontrol noktas\u0131 inhibit\u00f6r\u00fc taraf\u0131ndan aktive edilebilen, t\u00fcm\u00f6r infiltre edici lenfositler (TIL’ler) olarak adland\u0131r\u0131lan y\u00fcksek seviyelerde T h\u00fccrelerine sahip olma e\u011filimindedir. <\/span><\/span>Journal of Cancer Immunotherapy’de<\/span><\/span><\/em> yay\u0131nlanan bir makalede <\/span>, ara\u015ft\u0131rmac\u0131lar “y\u00fcksek TIL’li t\u00fcm\u00f6rlerin daha y\u00fcksek PD-L1 ekspresyonuna sahip olabilece\u011fini ve bu nedenle \u00fc\u00e7l\u00fc negatif meme kanserinin inhibit\u00f6r tedavisine en g\u00fc\u00e7l\u00fc klinik yan\u0131t\u0131 g\u00f6stermesinin nedeni olabilece\u011fini” \u00f6ne s\u00fcrd\u00fcler. ba\u011f\u0131\u015f\u0131kl\u0131k kontrol noktas\u0131, ancak daha fazla ara\u015ft\u0131rmaya ihtiya\u00e7 var.”<\/span><\/span><\/p>\n

Kontrol noktas\u0131 inhibit\u00f6rlerinin kullan\u0131m\u0131 ne zaman \u00f6nerilir?<\/span><\/span><\/h2>\n

Bununla birlikte, baz\u0131 meme kanseri hastalar\u0131, belirli durumlarda kontrol noktas\u0131 inhibit\u00f6rleri ile tedavi edilebilir. <\/span>\u00d6rne\u011fin:<\/span><\/span><\/p>\n

Hasta, t\u00fcm\u00f6r\u00fc belirli bir genetik \u00f6zelli\u011fe sahip oldu\u011fu i\u00e7in onayl\u0131 imm\u00fcnoterapiye uygundur. <\/span><\/span><\/strong>May\u0131s 2017’de ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA), bir t\u00fcm\u00f6r\u00fcn birincil b\u00f6lgesine de\u011fil, kanserin DNA’s\u0131nda bulunan spesifik bir genetik \u00f6zelli\u011fe dayal\u0131 bir kanser \u00f6nleyici ilac\u0131 onaylama konusunda \u00f6nemli bir ad\u0131m att\u0131. <\/span>Onay, brolizumab\u0131n (Keytruda <\/span><\/span>\u00ae<\/span><\/span><\/sup> ) iki spesifik genetik \u00f6zellikten birine sahip t\u00fcm\u00f6rleri olan hastalar\u0131 tedavi <\/span>etmesine izin verir <\/span>: mikro uydu karars\u0131zl\u0131\u011f\u0131 (MSI-H) veya uyumsuzluk onar\u0131m eksikli\u011fi (dMMR). <\/span>Bu gen mutasyonlar\u0131 daha \u00e7ok mide kanserlerinde bulunur, ancak bazen meme ve di\u011fer kanserlerde de bulunurlar.<\/span><\/span><\/p>\n

Baz\u0131 hastalar klinik ara\u015ft\u0131rma i\u00e7in uygun olabilir. <\/span><\/span><\/strong>\u015eu anda d\u00fczinelerce deneme, meme kanseri i\u00e7in potansiyel tedaviler olarak \u00e7e\u015fitli kontrol noktas\u0131 inhibit\u00f6rlerini ara\u015ft\u0131r\u0131yor. <\/span>\u0130la\u00e7lar, di\u011fer kontrol noktas\u0131 inhibit\u00f6rlerinin yan\u0131 s\u0131ra kemoterapi gibi di\u011fer tedavilerle kombinasyon halinde kendi ba\u015flar\u0131na test edilir. <\/span>Deneyim, bir doktorun ila\u00e7lar\u0131 etiket d\u0131\u015f\u0131 bir tedavi olarak re\u00e7ete etmesine izin verebilir. <\/span>Bu, G\u0131da ve \u0130la\u00e7 \u0130daresi taraf\u0131ndan imm\u00fcnoterapi i\u00e7in onaylanmam\u0131\u015f bir kanser t\u00fcr\u00fcn\u00fc tedavi etmek i\u00e7in ila\u00e7 re\u00e7ete etme uygulamas\u0131d\u0131r. <\/span>\u00d6rne\u011fin, antikanser ila\u00e7lar\u0131, Hedef Ajanlar ve Profil Olu\u015fturma Kullan\u0131m Kayd\u0131 (TAPUR) \u00e7al\u0131\u015fmas\u0131na kat\u0131lan hastalara, bunlar\u0131 hastalar\u0131n t\u00fcm\u00f6rlerinde bulunan spesifik genetik mutasyonlarla e\u015fle\u015ftirerek re\u00e7ete edilebilir.<\/span><\/span><\/p>\n

“Yay\u0131nlanan veriler, \u00fc\u00e7l\u00fc negatif meme kanserinde di\u011fer tiplere g\u00f6re daha fazla yan\u0131t oldu\u011funu g\u00f6steriyor, ancak veriler hala erken” dedi. <\/span>“Hala daha fazla zamana ihtiyac\u0131m\u0131z var. Ancak bir\u00e7ok \u00e7al\u0131\u015fma devam ediyor.”<\/span><\/span><\/p>\n

Meme kanseri ile ilgili \u00f6nemli sorular\u0131n yan\u0131tlar\u0131n\u0131 al\u0131n.<\/span><\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor T , farkl\u0131 kanser t\u00fcrlerine sahip baz\u0131 hastalar i\u00e7in d\u00fczinelerce yeni tedavi se\u00e7ene\u011fiyle imm\u00fcnoterapi \u00e7a\u011f\u0131n\u0131 vaaz etti. ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA), ilk kontrol noktas\u0131 inhibit\u00f6r\u00fcn\u00fc onaylad\u0131: ipilimumab (Yervoy \u00ae ) \u2014 2011’de metastatik melanomlu hastalar\u0131 tedavi etmek i\u00e7in. \u015eu anda, onaylanm\u0131\u015f kontrol noktas\u0131 inhibit\u00f6rlerinin alt\u0131s\u0131, en yayg\u0131n …<\/p>\n","protected":false},"author":1,"featured_media":23569,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":["post-23881","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized-tr"],"yoast_head":"\nMeme kanseri i\u00e7in imm\u00fcnoterapi hala zor - zdmaa<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor - zdmaa\" \/>\n<meta property=\"og:description\" content=\"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor T , farkl\u0131 kanser t\u00fcrlerine sahip baz\u0131 hastalar i\u00e7in d\u00fczinelerce yeni tedavi se\u00e7ene\u011fiyle imm\u00fcnoterapi \u00e7a\u011f\u0131n\u0131 vaaz etti. ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA), ilk kontrol noktas\u0131 inhibit\u00f6r\u00fcn\u00fc onaylad\u0131: ipilimumab (Yervoy \u00ae ) \u2014 2011’de metastatik melanomlu hastalar\u0131 tedavi etmek i\u00e7in. \u015eu anda, onaylanm\u0131\u015f kontrol noktas\u0131 inhibit\u00f6rlerinin alt\u0131s\u0131, en yayg\u0131n …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/\" \/>\n<meta property=\"og:site_name\" content=\"zdmaa\" \/>\n<meta property=\"article:published_time\" content=\"2022-01-12T17:25:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-01-12T20:04:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png\" \/>\n\t<meta property=\"og:image:width\" content=\"407\" \/>\n\t<meta property=\"og:image:height\" content=\"640\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tahmini okuma s\u00fcresi\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 dakika\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/\",\"url\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/\",\"name\":\"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor - zdmaa\",\"isPartOf\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png\",\"datePublished\":\"2022-01-12T17:25:35+00:00\",\"dateModified\":\"2022-01-12T20:04:23+00:00\",\"author\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\"},\"breadcrumb\":{\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#primaryimage\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png\",\"width\":407,\"height\":640,\"caption\":\"Immunotherapy For Breast Cancer Remains Elusive\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629\",\"item\":\"https:\/\/zdmaa.com\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#website\",\"url\":\"https:\/\/zdmaa.com\/tr\/ro\/\",\"name\":\"zdmaa\",\"description\":\"zdmaa\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700\",\"contentUrl\":\"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/zdmaa.com\"],\"url\":\"https:\/\/zdmaa.com\/tr\/author\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor - zdmaa","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/","og_locale":"tr_TR","og_type":"article","og_title":"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor - zdmaa","og_description":"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor T , farkl\u0131 kanser t\u00fcrlerine sahip baz\u0131 hastalar i\u00e7in d\u00fczinelerce yeni tedavi se\u00e7ene\u011fiyle imm\u00fcnoterapi \u00e7a\u011f\u0131n\u0131 vaaz etti. ABD G\u0131da ve \u0130la\u00e7 Dairesi (FDA), ilk kontrol noktas\u0131 inhibit\u00f6r\u00fcn\u00fc onaylad\u0131: ipilimumab (Yervoy \u00ae ) \u2014 2011’de metastatik melanomlu hastalar\u0131 tedavi etmek i\u00e7in. \u015eu anda, onaylanm\u0131\u015f kontrol noktas\u0131 inhibit\u00f6rlerinin alt\u0131s\u0131, en yayg\u0131n …","og_url":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/","og_site_name":"zdmaa","article_published_time":"2022-01-12T17:25:35+00:00","article_modified_time":"2022-01-12T20:04:23+00:00","og_image":[{"width":407,"height":640,"url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"admin","Tahmini okuma s\u00fcresi":"4 dakika"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/","url":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/","name":"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor - zdmaa","isPartOf":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#website"},"primaryImageOfPage":{"@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#primaryimage"},"image":{"@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#primaryimage"},"thumbnailUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png","datePublished":"2022-01-12T17:25:35+00:00","dateModified":"2022-01-12T20:04:23+00:00","author":{"@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3"},"breadcrumb":{"@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#primaryimage","url":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png","contentUrl":"https:\/\/zdmaa.com\/wp-content\/uploads\/2022\/01\/breast-feeding-ge945da2d2_640.png","width":407,"height":640,"caption":"Immunotherapy For Breast Cancer Remains Elusive"},{"@type":"BreadcrumbList","@id":"https:\/\/zdmaa.com\/tr\/immunotherapy-for-breast-cancer-remains-elusive\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0627\u0644\u0631\u0626\u064a\u0633\u064a\u0629","item":"https:\/\/zdmaa.com\/tr\/"},{"@type":"ListItem","position":2,"name":"Meme kanseri i\u00e7in imm\u00fcnoterapi hala zor"}]},{"@type":"WebSite","@id":"https:\/\/zdmaa.com\/tr\/ro\/#website","url":"https:\/\/zdmaa.com\/tr\/ro\/","name":"zdmaa","description":"zdmaa","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/zdmaa.com\/tr\/ro\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/8aad4cf5d562d4ca835487f6149853e3","name":"admin","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/zdmaa.com\/tr\/ro\/#\/schema\/person\/image\/","url":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700","contentUrl":"https:\/\/zdmaa.com\/wp-content\/litespeed\/avatar\/dff6d89ac221c1aaf9366bf5b4cd32de.jpg?ver=1775954700","caption":"admin"},"sameAs":["https:\/\/zdmaa.com"],"url":"https:\/\/zdmaa.com\/tr\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/23881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/comments?post=23881"}],"version-history":[{"count":2,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/23881\/revisions"}],"predecessor-version":[{"id":23923,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/posts\/23881\/revisions\/23923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media\/23569"}],"wp:attachment":[{"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/media?parent=23881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/categories?post=23881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/zdmaa.com\/tr\/wp-json\/wp\/v2\/tags?post=23881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}